Get the Stockscreener App
23.60
2.61%
0.60
After Hours:
23.33
-0.27
-1.14%
Ultragenyx Pharmaceutical Inc stock is traded at $23.60, with a volume of 3.64M.
It is up +2.61% in the last 24 hours and down -29.49% over the past month.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
See More
Previous Close:
$23.00
Open:
$22.84
24h Volume:
3.64M
Relative Volume:
1.90
Market Cap:
$2.28B
Revenue:
$610.16M
Net Income/Loss:
$-532.93M
P/E Ratio:
-4.2686
EPS:
-5.5287
Net Cash Flow:
$-442.30M
1W Performance:
-30.97%
1M Performance:
-29.49%
6M Performance:
-40.19%
1Y Performance:
-42.65%
1-Day Range:
$22.50
$24.00
1-Week Range:
$18.41
$24.00
52-Week Range:
$18.41
$46.50
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Name
Ultragenyx Pharmaceutical Inc
Sector
Industry
Phone
415-483-8800
Address
60 LEVERONI COURT, NOVATO, CA
Compare RARE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
23.60 | 2.22B | 610.16M | -532.93M | -442.30M | -5.5287 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Jul-28-25 | Resumed | H.C. Wainwright | Buy |
| May-28-25 | Initiated | William Blair | Outperform |
| Jun-06-24 | Upgrade | Goldman | Neutral → Buy |
| Apr-22-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Jun-06-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Dec-30-22 | Resumed | H.C. Wainwright | Buy |
| Nov-03-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-01-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-16-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Feb-11-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-30-21 | Initiated | H.C. Wainwright | Buy |
| Aug-19-21 | Initiated | UBS | Sell |
| Jul-15-21 | Initiated | Guggenheim | Neutral |
| Jun-29-21 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| May-06-21 | Upgrade | Citigroup | Neutral → Buy |
| May-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-02-21 | Resumed | Stifel | Buy |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-24-20 | Resumed | Evercore ISI | In-line |
| Nov-12-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-19 | Resumed | Wedbush | Outperform |
| Mar-27-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-22-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-08-18 | Upgrade | Citigroup | Sell → Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-18 | Upgrade | Barclays | Equal Weight → Overweight |
| May-10-18 | Initiated | Goldman | Neutral |
| Apr-18-18 | Upgrade | SunTrust | Hold → Buy |
| Mar-22-18 | Resumed | Piper Jaffray | Overweight |
| Feb-21-18 | Reiterated | Stifel | Buy |
| Jan-22-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-18-18 | Initiated | Credit Suisse | Outperform |
| Dec-05-17 | Reiterated | Barclays | Equal Weight |
| Dec-04-17 | Upgrade | Jefferies | Hold → Buy |
| Sep-14-17 | Upgrade | Wedbush | Neutral → Outperform |
View All
Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News
StockWatch: Ultragenyx, Mereo Plummet on Brittle Bone Candidate Failures - Genetic Engineering and Biotechnology News
ATTENTION RARE Shareholders: Lost Money on Ultragenyx Pharmaceutical Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Ultragenyx granted FDA priority review for gene therapy in rare brain disorder - MSN
Benzinga Bulls And Bears: Nike, SpaceX, Ultragenyx — And Chinese Tech Stocks Slide - Benzinga
ATTENTION Ultragenyx Pharmaceutical Inc. (RARE) Investors: Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Ultragenyx stock eyes best day in 17 months as Wall Street shifts focus to 2026 pipeline after bone disease trial miss - MSN
Levi & Korsinsky Investigates Possible Securities Fraud by Ultragenyx Pharmaceutical Inc. (RARE) - ACCESS Newswire
Ultragenyx Phase III Data Reveal Limits of Bone Density Endpoints in Rare Bone Disease - BioPharm International
Bank of America Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $58.00 - MarketBeat
Ultragenyx Pharmaceutical (RARE): B of A Securities Lowers Price Target | RARE Stock News - GuruFocus
Ultragenyx completes rolling submission of BLA for DTX401 - The Pharma Letter
Ultragenyx Pharmaceuticals Loses $1 Billion in Market Value After Bone Drug Fails Phase III Trials - geneonline.com
BofA Securities lowers Ultragenyx Pharma stock price target on failed trials By Investing.com - Investing.com South Africa
Ultragenyx Loses $1B in Market Value as Bone Drug Fails To Reduce Fractures - BioSpace
These nine Bay Area drug makers are hurtling toward key FDA approval decisions in 2026 - The Business Journals
BofA Securities lowers Ultragenyx Pharma stock price target on failed trials - Investing.com
Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? - RTTNews
Ultragenyx plans cost-cutting push after flunking phase 3 trials - Fierce Biotech
Analysts Are Bullish on Top Healthcare Stocks: Tectonic Therapeutic (TECX), Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Biggest stock movers Monday: DigitalBridge, Ultragenyx Pharmaceutical - MSN
Ultragenyx’s Setrusumab falls short in Phase 3 osteogenesis imperfecta trials - Indian Pharma Post
RARE Rises on Completion of Rolling Submission for AAV Gene Therapy - The Globe and Mail
Lacklustre Performance Is Driving Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 32% Price Drop - 富途牛牛
Analysts’ Top Healthcare Picks: Ultragenyx Pharmaceutical (RARE), Zevra Therapeutics (ZVRA) - The Globe and Mail
Ultragenyx recovers some losses as Jefferies sees potential 2026 rebound - MSN
Ultragenyx (RARE) Completes U.S. Application for Gene Therapy DT - GuruFocus
Ultragenyx completes rolling FDA submission for US approval of gene therapy - Seeking Alpha
Ultragenyx stock today: RARE steadies premarket after setrusumab Phase 3 miss, FDA gene-therapy filing in focus - ts2.tech
Ultragenyx (RARE) Moves 15.5% Higher: Will This Strength Last? - Yahoo Finance
Ultragenyx (RARE) Rockets 15.5% on Bargain-Hunting After Steep Fall - Finviz
Ultragenyx (RARE) rockets 15.5% on bargain-hunting after steep fall - MSN
Why Ultragenyx Pharmaceuticals stock is plummeting today - MSN
Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Why Did RARE Stock Plunge Over 41% Today? - Stocktwits
Shareholders Alert: Investigation Into Ultragenyx Pharmaceutical Inc. (RARE)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Ultragenyx completes BLA submission for GSDIa gene therapy By Investing.com - Investing.com Nigeria
Why Ultragenyx Pharmaceutical stock is bouncing back today - MSN
Ultragenyx Completes Rolling Submission of Biologics License Application for DTX401 Gene Therapy - marketscreener.com
Ultragenyx completes BLA filing for GSDIa gene therapy - TipRanks
Ultragenyx (RARE) Completes Key FDA Submission for Gene Therapy Approval - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - FinancialContent
Ultragenyx completes BLA submission for GSDIa gene therapy - Investing.com
Ultragenyx Pharmaceutical Sees Unusually Large Options Volume (NASDAQ:RARE) - MarketBeat
Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) - The Globe and Mail
Ultragenyx Pharmaceutical Inc. Completes Rolling Submission of BLA for DTX401 Gene Therapy to Treat Glycogen Storage Disease Type Ia - Quiver Quantitative
Ultragenyx Pharmaceutical Completes BLA Submission for DTX401 - TradingView — Track All Markets
Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today - AOL.com
Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for ... - Caledonian Record
Ultragenyx Completes Rolling Submission of Biologics - GlobeNewswire
Why Ultragenyx stock dropped 42% and what comes next - MSN
Ultragenyx SVP Huizenga sells $2922 in shares By Investing.com - Investing.com Nigeria
Ultragenyx Pharmaceutical Inc Stock (RARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):